Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the placebo ...

Nov. 22, 2002 — Rivastigmine (Exelon), which was developed for treatment of Alzheimer's disease, also is beneficial in subcortical vascular dementia, according to results of an open-label study ...

Rivastigmine MD is soon to start phase III clinical trials in Japan. Luye Pharma also plans to register this product in the U.S. and other countries. About Italfarmaco Group.

Rivastigmine plus citalopram did not have superior efficacy compared with rivastigmine alone among individuals with Alzheimer’s disease, according to data presented at the American Academy of ...

Espay and colleagues conducted a post-hoc analysis of two randomized, controlled trials that compared rivastigmine vs. placebo at week 24 (n = 501) and rivastigmine patch vs. capsule at week 76 (n ...

Treatment with high doses of the acetylcholinesterase inhibitor rivastigmine (Exelon, Novartis Pharmaceuticals) reduces falls in patients with Parkinson's disease (PD), a new phase 2 study ...

May 4, 2009 -- Question: What is Exelon (rivastigmine), how does it work and when is it used? Answer: Exelon is the brand name of rivastigamine, another of the cholinesterase inhibitors.As with ...

Neurologist Martin Farlow, M.D., of Indiana University School of Medicine reports that patients treated daily with 6 mg. to 12 mg. of rivastigmine had significantly better cognitive function over ...